Gene Therapies in Degenerative Retinal Disease Hold
Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME...
Source: globenewswire.com
Retinal Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Retinal Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Retinal Disorders Today - Breaking & Trending Today
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on October 27, 2023, from Atlas Special Opportuni
Source: yahoo.com
Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program
EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”). On Septe
Source: yahoo.com
Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program
EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”). On Septe
Source: yahoo.com
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on September 14, 2023, from Atlas Special Oppor
Source: yahoo.com